BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eucrisa (crisaborole) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eucrisa (crisaborole)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07892339-1346@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Eucrisa (crisaborole): Phase 3 readout est. (NCT07892339)
DESCRIPTION:Eucrisa (crisaborole)\, phase 3.\nStudy: Efficacy of Crisaborol
 e 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertri
 ginous and/or Anogenital Psoriasis.\nEstimated primary completion: 13 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/crisaborol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 892339
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162896-1346@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Eucrisa (crisaborole): Phase 3 readout est. (NCT07162896)
DESCRIPTION:Eucrisa (crisaborole)\, phase 3\, Atopic Dermatitis.\nStudy: Cr
 isaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atop
 ic Dermatitis\nEstimated primary completion: January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/crisaborole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07162896
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-1346@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Eucrisa (crisaborole): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Eucrisa (crisaborole)\, phase 4\, Atopic Dermatitis.\nStudy: Ut
 ilization of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated 
 primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/crisaborole#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/crisaborole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
